Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

UCB and Nodality Enter into a Multi-Year Strategic Collaboration

Published: Friday, February 10, 2012
Last Updated: Friday, February 10, 2012
Bookmark and Share
Partnership utilizes Nodality’s SCNP technology to assist the development of several UCB compounds.

UCB Pharma S.A. and Nodality, Inc. have announced a strategic collaboration utilizing Nodality’s proprietary Single Cell Network Profiling (SCNP) technology to assist the development of several UCB compounds.

The agreement establishes a multi-year collaborative investigation focusing initially on immunology disorders.

Based on information generated using Nodality’s technology, the agreement also gives UCB the option to engage Nodality to develop companion diagnostics for UCB’s compounds.

The terms of the agreement, whose details are not disclosed, include an upfront payment, R&D funding, and success-based milestones if all applicable development, regulatory and commercialization milestones are achieved.

In addition, Nodality may be eligible for royalties on future diagnostic sales.

David Parkinson, MD, Chief Executive Officer of Nodality, said, “We are delighted to be working together with UCB’s world class immunology research group to enhance their drug development activities. Based on Nodality’s extensive application of the SCNP platform to malignant and autoimmune diseases, we believe that we will be able to add significant value to UCB’s drug development portfolio. This collaboration is validation of Nodality’s unique technological approach and of the value the SCNP platform technology can bring to pharmaceutical drug development. We look forward to a close and productive working relationship with UCB’s research and development teams."

Ismail Kola, Executive Vice President and President, NewMedicines at UCB said, “We look forward to the Nodality collaboration as we advance UCB’s Research & Development pipeline. This collaboration represents a key component of UCB’s strategy to innovate on the paradigm of drug development through an enhanced understanding of disease pathways and drug mechanisms in order to realize the potential for patient stratification, targeted treatments and improved care for patients.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

UCB and Oxford University Announce New R&D Partnership
New collaboration to develop innovative research in immunology and neurology.
Monday, April 02, 2012
Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
New Hope for Personalized Treatment of Eczema
Pharmaceutical researchers at Oregon State University have developed a new approach to treat eczema and other inflammatory skin disorders that would use individual tests and advanced science to create personalized treatments based on each person's lipid deficiencies.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Combination Drug Therapy Shrinks Pancreatic Tumors In Mice
Two drugs that affect the structure and function of DNA have been found to block the growth of pancreatic tumor cells in mice, researchers hope the drugs can soon be tested in humans with the disease.
Seeking A Better Way To Design Drugs
NIH funds research at Worcester Polytechnic Institute to advance a new chemical process for more effective drug development and manufacturing.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Diabetes Drugs May Actually Release Sugar Into the Blood
A family of drugs used to treat Type 2 diabetes could promote the release of sugars into the blood - something the drugs are supposed to prevent, Cambridge scientists have claimed.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos